FDA Approves First Treatment for Agitation Associated with Alzheimer’s Dementia Posted byJoseph Thornton MDMay 11, 2023Posted inBlog https://www.neiglobal.com/Members/MonthInPsychopharmPost/tabid/509/topic/20744/Default.aspx?utm_source=facebook&utm_medium=social Joseph Thornton Share this: Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook Like Loading... Related Published by Joseph Thornton MD Teacher, Clinical Supervisor, [AIdvisor] Retired Clinical Associate Professor, Psychiatry, University of Florida Affiliation is for identification only. All content and opinions are my own. View more posts
Gator Psychiatry 